1. Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve
- Author
-
Maria Vittoria Cicinelli, Marco Battista, Alessandro Marchese, Elisabetta Miserocchi, Luigi Capone, Giulio Modorati, Francesco Bandello, Vincenzo Starace, Battista, M., Starace, V., Cicinelli, M. V., Capone, L., Marchese, A., Modorati, G., Bandello, F., and Miserocchi, E.
- Subjects
Area under the curve ,Intraocular pressure ,medicine.medical_specialty ,Fluocinolone acetonide implant ,Visual acuity ,genetic structures ,business.industry ,medicine.disease ,eye diseases ,Non-infectious posterior uveitis ,Chronic macular edema ,Posterior segment of eyeball ,Ophthalmology ,Fluocinolone acetonide ,medicine ,sense organs ,Implant ,medicine.symptom ,business ,Macular edema ,Uveitis ,Original Research ,medicine.drug - Abstract
Introduction This study reports the outcomes of fluocinolone acetonide intravitreal implant (FAc, Iluvien®, SIFI, Italy) in patients affected by macular edema secondary to chronic non-infectious uveitis of the posterior segment (NIU-PS). Methods This was a retrospective study of patients with NIU-PS and macular thickening undergoing FAc implant at San Raffaele Hospital (Milan, Italy). Clinical data, including best-corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT), were collected at the time of FAc administration (baseline) and at 1, 6, and 12 months. The area under the curve (AUC) of the BCVA (AUCBCVA) and CMT (AUCCMT) was correlated with baseline factors; β estimates and 95% confidence interval (CI) are provided. Results Ten eyes of seven patients (60 ± 12 years; 4 male, 57%) were included. The BCVA significantly improved from month 6 (p = 0.03). The CMT improved from month 1 and was persistently lower than baseline until month 12 (p
- Published
- 2022